The London Breast Institute – New Concept To Raise Standards For Breast Cancer Diagnosis, Treatment And Research In The Independent Sector, UK

The London Breast Institute is launched today at the private Princess Grace Hospital in central London. The Institute brings together world-renowned specialists in the field of breast cancer and represents a significant development in the treatment of breast disease in the independent sector in the UK.

With an already excellent clinical track record in the diagnosis and treatment of all forms of breast disease, specialised medical staff at the hospital’s breast care centre have partnered with the academic and research skills of internationally renowned breast disease centres and the medical diagnostic industry to bring together a team of experts and specialists with a range of clinical, academic and research skills that has not previously existed in the independent sector.

The London Breast Institute will also work closely with and foster links throughout the central London HCA International hospital network including the London Cancer Centre at the Harley St Clinic and the breast care programme at the Portland Hospital for Women and Children.

Speaking at an international symposium held in central London today, Dr Nick Perry, Consultant Radiologist and Director of the Institute declared that “The London Breast Institute will set new standards for the diagnosis, treatment and clinical care of breast disease. We will use the vast amount of clinical data gathered at the hospital including 35,000 digital mammograms and the clinical records of hundreds of women diagnosed with breast cancer, many from younger age groups, to publish research and further the diagnosis and treatment of breast disease. With the help and support of our chosen technology partners, GE Healthcare and Suros Surgical Systems, we will use the latest diagnostic equipment and imaging technologies to undertake clinical trials of techniques and diagnostic procedures for the benefit of all patients with breast disease.”

Research and Publications

The Institute has already commenced two cutting-edge research projects – firstly a trial to investigate the impact of digital mammography on breast cancer detection rates in routine screening, and secondly a project to investigate whether women living in an urban environment are at greater risk of breast cancer due to having denser breast tissue than non-urban women. The outcomes of these research activities are expected to have implications for the screening choices and behaviours of all women over 40.

An international research board is being appointed to supervise and publish the Institute’s research findings and an open, annual scientific meeting will be held to encourage the medical profession to engage with the Institute’s aims and objectives.

Our Technology Partners

GE Healthcare, a division of the General Electric Company, will join forces with the London Breast Institute to identify advances in the detection and diagnosis of breast cancer. GE Healthcare is a leading developer and manufacturer of x-ray, ultrasound and MRI systems used in breast care units and national screening services worldwide; the Princess Grace Hospital was the first breast unit in the UK to switch from film-based detection to digital, using GE Healthcare’s SenographeTM digital x-ray mammography system. A major recent study by the US National Cancer Institute showed that women with dense breasts, women younger than 50 and those who are perimenopausal may benefit from digital mammograms. Through joint studies, GE Healthcare and the London Breast Institute hope to identify further new ways of detecting breast cancer in its early stages and to improve the management of women diagnosed with the disease.

David Caumartin, Global Leader for Mammography, GE Healthcare said “By working together with the world class team at the London Breast Institute, we hope to increase our ability to detect breast cancer earlier, to give women the very best chance of survival. The combination of expertise will be a powerful force in improving the early diagnosis of this life-threatening disease”.

Suros Surgical Systems, Inc. A major advance in clinical equipment, the Suros ATEC® breast biopsy system enables clinicians to accurately biopsy suspicious lesions or remove non-cancerous masses of the breast in a minimally invasive way. Lumps can be removed quickly and efficiently under local anaesthetic without surgery, general anaesthetic, post-procedure scarring or an inpatient stay.

About The Princess Grace Hospital

Part of HCA International, The Princess Grace Hospital is an acute care, multi-disciplinary private facility in central London with over 25 years’ experience. It has 110 beds, including intensive care, a high dependency unit and one of the most advanced and best-equipped diagnostic imaging departments in the capital. For further information, please see The Princess Grace Hospital website at: theprincessgracehospital.

Multi-disciplinary care, treatment and advice are available quickly and efficiently – a consultant is on hand 24 hours a day, 52 weeks a year.

The Breast Care Centre provides a full range of treatment and diagnostic options under one roof, and has the latest technology and a multi-disciplinary care team comprising radiographers, radiologists, surgeons, oncologists, cytologists, histopathologists and breast nurse counsellors. Together they work with each patient to determine the best treatment, for the best outcomes.

About GE Healthcare

GE Healthcare provides transformational medical technologies and services that are shaping a new age of patient care. Our expertise in medical imaging and information technologies, medical diagnostics, patient monitoring systems, performance improvement, drug discovery, and biopharmaceutical manufacturing technologies is helping clinicians around the world re-imagine new ways to predict, diagnose, inform, treat and monitor disease, so patients can live their lives to the fullest.

GE Healthcare’s broad range of products and services enable healthcare providers to better diagnose and treat cancer, heart disease, neurological diseases and other conditions earlier. Our vision for the future is to enable a new “early health” model of care focused on earlier diagnosis, pre-symptomatic disease detection and disease prevention. Headquartered in the United Kingdom, GE Healthcare is a $17 billion unit of General Electric Company (NYSE: GE). Worldwide, GE Healthcare employs more than 46,000 people committed to serving healthcare professionals and their patients in more than 100 countries. For more information about GE Healthcare, visit our website at gehealthcare.

About Suros Surgical Systems, Inc.

Suros Surgical Systems, Inc. is a subsidiary of women’s imaging leader, Hologic, Inc. (NASDAQ: HOLX). Suros is a leading innovator in the field of devices used for minimally invasive breast biopsy and tissue excision. The company designs, manufactures and markets patient-focused and physician-inspired “Compassionate Technologies” through its ATEC (Automated Tissue Excision and Collection) product line compatible with stereotactic x-ray, ultrasound and magnetic resonance imaging (MRI) systems and its ultrasound-only Celero™ device. Suros is viewed worldwide as the pioneer and market leader in MRI-guided breast biopsy technology and is the fastest growing choice in vacuum-assisted breast biopsy. For more information about Suros and its breast biopsy systems, visit SurosSurgical.

This entry was posted in Uncategorized. Bookmark the permalink.